Deficits in lipid lowering therapy and achieving target lipid concentrations in patients with high risk of a cardiovascular event

Česká verzia

Authors: J. Petrus ¹; F. Málek ¹; J. Dvořák ² ; M. Mates ¹; P. Kmoníček ¹; V. Skalníková ¹; P. Neužil ¹
Authors place of work: Kardiovaskulární centrum Nemocnice Na Homolce Praha, přednosta MUDr. Štěpán Černý, CSc. ¹; Státní zdravotní ústav Praha, ředitelka Ing. Jitka Sosnovcová ²
Published in the journal: Vnitř Lék 2012; 58(6): 430-433
Category: Original Contributions

Summary

Lipid concentrations were analysed in 529 consecutive patients, 190 females (34%) and 339 males (66%) with mean age 66 years, at high cardiovascular risk, undergoing elective coronary angiography between 1st January and 31st May 2010. LDL-cholesterol level < 2,5 mmol/l was identified only in 36% of patients in primary prevention, LDL-cholesterol level < 2,0 mmol/l was identified only in 28% of subjects in secondary prevention of cardiovascular events. The study proves inadequate control of dyslipidaemia in patients at high cardiovascular risk.

Key words:
lipids – hypolipidemic therapy – lipid targets – cardiovascular risk

Zdroje

1. Gould AL, Rossouw JE, Santanello NC et al. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998; 97: 946–952.

2. Pedersen TR, Kjekshus J, Berg K et al. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Atheroscler Suppl 2004; 5:81–87.

3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357.

4. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–1009.

5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22.

6. LaRosa JC, Grundy SM, Waters DD et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–1435.

7. Vaverková H, Soška V, Rosolová H et al. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu Cor Vasa 2007; 49: K73–K86.

8. Cífková R, Býma S, Češka R et al. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. Vnitř Lék 2005; 51:1021–1036.

9. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2011; 32: 1769–1818.

10. Pearson TA, Laurora I, Chu H et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459–467.

11. Klinke JA, Málek F, Gao M et al. Reaching Target Lipid Levels in Patients at High Risk of Cardiovascular Event: the Experience of a Canadian Tertiary Care Lipid Clinic. Centr Eur J Public Health 2007; 15: 106–109.

12. Málek F, Dvořák J, Strieborná H et al. Reaching target lipid levels and the natural history of diabetes mellitus in patients surviving acute coronary syndrome: A retrospective cohort study from a tertiary care outpatient clinic. Exp Clin Cardiol 2008; 13: 25–28.

13. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systemic review and metaanalysis. BMJ 2003; 326: 1423–1430.

14. Conroy R, Pyörälä K, Fitzgerald AP et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.

15. Jones PH, Davidson MH, Stein EA et al. STELLAR Study Group. Comparison of the Efficacy and Safety of Rosuvastatin Versus Atorvastatin, Simvastatin, and Pravastatin Across Doses (STELLAR Trial). Am J Cardiol 2003; 92: 152–160.

16. Andrews TC, Ballantyne CM, Hsia JA et al. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001; 111: 185–194.

17. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996; 100: 197–204.

18. Taher TH, Dzavik V, Reteff EM et al. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. Am J Cardiol 2002; 89: 390–394.

19. Widimský J, Vaněk P, Juráň F et al. Current status of cardiovascular pharmacotherapy in patients after myocardial infarction and/or revascularization in the Czech Republic in 2005. Developments seen during the past 5 and 10 years. Cor Vasa 2006; 48: 135–141.

20. Nissen SE, Tuzcu EM, Schoenhagen P et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on pregression of coronary atherosclerosis. A randomized controlled trial. JAMA 2004; 291: 1071–1080.

21. Nissen S, Nicholls SJ, Sipahi I et al. ASTEROID Investigators. Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis. The ASTEROID Trial. JAMA 2006; 295: 1556–1565.